| 2026-08-06 | Press release | Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming S |
| 2026-08-05 | Press release | Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG |
| 2026-07-07 | Press release | PDF view of form 425 filed on Jul 7, 2026 |
| 2026-07-07 | Press release | Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderl |
| 2026-06-30 | Press release | PDF view of form 425 filed on Jun 24, 2026 |
| 2026-06-24 | Press release | Onconetix Highlights Realbotix's Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State Scho |
| 2026-06-16 | Prospectus | PDF view of form 424B3 filed on Jun 17, 2026 |
| 2026-05-19 | Press release | Onconetix, Inc. Announces 1-for-10 Reverse Stock Split |
| 2026-05-13 | Press release | Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S |
| 2026-05-07 | Prospectus | PDF view of form 424B3 filed on May 12, 2026 |
| 2026-04-02 | Press release | Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update |
| 2026-03-31 | Press release | Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors |
| 2026-03-23 | Press release | Onconetix, Inc. Announces 1-for-5 Reverse Stock Split |
| 2026-02-12 | Press release | Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics Company |
| 2025-09-26 | Press release | Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termin |
| 2025-09-26 | Press release | Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement |
| 2025-09-22 | Press release | Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently p |
| 2025-06-16 | Press release | Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel |
| 2025-06-11 | Press release | Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders |
| 2025-05-22 | Press release | Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq |
| 2025-04-30 | Press release | Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq |
| 2025-04-08 | Press release | Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc. |
| 2025-03-24 | Press release | Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort |
| 2025-03-19 | Press release | Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 202 |
| 2024-10-03 | Press release | Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establi |
| 2024-10-03 | Press release | Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establi |
| 2024-10-03 | Press release | Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warra |
| 2024-09-20 | Press release | Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders |
| 2024-09-20 | Press release | Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders |
| 2024-07-15 | Press release | Onconetix Announces Closing of Warrant Exercise for $1.11 Million Gross Proceeds |
| 2024-07-15 | Press release | Onconetix Announces Closing of Warrant Exercise for $1.11 Million Gross Proceeds |
| 2024-07-11 | Press release | Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds |
| 2024-07-11 | Press release | Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds |
| 2024-02-13 | Press release | Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Direc |
| 2024-02-13 | Press release | Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Direc |
| 2023-12-19 | Press release | Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders |
| 2023-12-18 | Press release | Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name C |
| 2023-04-24 | Press release | Blue Water Vaccines Announces Corporate Name Change to Blue Water Biotech in Connection with Transition into Commercial- |
| 2023-04-20 | Press release | Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset |
| 2023-04-12 | Press release | Blue Water Vaccines Announces Signing of Sponsored Research Agreement with The University of Texas Health Science Center |